VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - July 12, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that the Company’s proprietary compound NAP has been shown in preclinical studies to be effective in reducing both amyloid plaques and neurofibrillary tangles in the brain, two pathologies most closely correlated with Alzheimer’s disease in humans.
